Erasca (ERAS) Other Non-Current Liabilities (2020 - 2026)
Erasca posted quarterly Other Non-Current Liabilities of $340000.0 for Q1 2026, up 35.46% year-on-year from $251000.0 in Q1 2025, and down 14.79% on a QoQ basis from $399000.0 in Q4 2025.
Erasca (ERAS) has 7 years of Other Non-Current Liabilities data on file, last reported at $340000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 35.46% year-over-year to $340000.0; the trailing twelve-month figure through Mar 2026 stood at $340000.0 (up 35.46% YoY), and the FY2025 full-year result was $399000.0, up 10.22% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $340000.0, down from $399000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $761000.0 in Q3 2023 and bottomed at $82000.0 in Q2 2024.
- The 5-year median for Other Non-Current Liabilities is $397000.0 (2025), against an average of $444142.9.
- The widest annual swing landed in 2022, when Other Non-Current Liabilities jumped 262.66%; it then sank 88.24% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $573000.0 in 2022, then slipped by 1.22% to $566000.0 in 2023, then slumped by 36.04% to $362000.0 in 2024, then advanced by 10.22% to $399000.0 in 2025, then declined by 14.79% to $340000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $340000.0 (Q1 2026), $399000.0 (Q4 2025), and $395000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 340,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 395,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Mar 31, 2025 | 251,000.00 |
| Dec 31, 2024 | 362,000.00 |
| Sep 30, 2024 | 340,000.00 |
| Jun 30, 2024 | 82,000.00 |
| Mar 31, 2024 | 559,000.00 |
| Dec 31, 2023 | 566,000.00 |
| Sep 30, 2023 | 761,000.00 |
| Jun 30, 2023 | 697,000.00 |
| Mar 31, 2023 | 630,000.00 |
| Dec 31, 2022 | 573,000.00 |
| Dec 31, 2021 | 158,000.00 |
| Dec 31, 2020 | 1.62 Mn |